Indolent Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Indolent Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-10-29Clinical Trial Update: Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) [Phase 2]
Phase 2 study MK-0683-103 evaluated vorinostat in follicular lymphoma, other indolent B-cell non-Hodgkin lymphomas, and mantle cell lymphoma…
-
CLINICAL_TRIALS withdrawal · 2020-10-19Clinical Trial Update: Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma [Phase 3]
A Phase 3 trial evaluating fludarabine and rituximab with or without pixantrone for relapsed/refractory indolent non-Hodgkin lymphoma has be…
-
CLINICAL_TRIALS trial_result · 2020-06-02Clinical Trial Update: Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies [Phase 2]
Phase 2 trial of Entospletinib plus Idelalisib in adults with relapsed or refractory hematologic malignancies was terminated; results posted…
-
CLINICAL_TRIALS trial_result · 2020-03-27Clinical Trial Update: Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy [Phase 3]
Phase 3 trial comparing ofatumumab-bendamustine versus bendamustine alone in rituximab-refractory indolent B-cell non-Hodgkin lymphoma was t…
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [Phase 2]
Phase 2 clinical trial update on donor umbilical cord blood transplant for hematologic cancers; status completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 clinical trial of duvelisib in participants with refractory indolent non-Hodgkin lymphoma has completed and results were posted in 2…
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 study evaluating bortezomib, rituximab, cyclophosphamide, and prednisone in relapsed or refractory indolent non-Hodgkin's lymphoma…
-
CLINICAL_TRIALS trial_result · 2018-09-04Clinical Trial Update: A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab. [Phase 3]
Phase 3 trial evaluating bendamustine in indolent non-Hodgkin's lymphoma refractory to rituximab; study terminated.
-
CLINICAL_TRIALS trial_result · 2018-07-06Clinical Trial Update: Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 clinical trial investigating vorinostat and rituximab in indolent non-Hodgkin lymphoma completed with results posted.
-
CLINICAL_TRIALS withdrawal · 2018-04-19Clinical Trial Update: Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas
A clinical trial evaluating interferon-free antiviral therapy for patients with Hepatitis C-positive genotype 1b–associated indolent non-Hod…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma [Phase 2]
This Phase 2 trial evaluated the combination of vorinostat, cladribine, and rituximab in patients with mantle cell lymphoma, relapsed chroni…
-
CLINICAL_TRIALS trial_result · 2017-10-31Clinical Trial Update: Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma [Phase 2]
Phase 2 study evaluating inotuzumab ozogamicin (CMC-544) in indolent non-Hodgkin lymphoma has completed and results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-10-13Clinical Trial Update: A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma [Phase 2]
A Phase II trial for indolent non-follicular non-Hodgkin's lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2017-05-11Clinical Trial Update: Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas [Phase 3]
Phase 3 trial evaluating idelalisib with bendamustine and rituximab in previously treated indolent non-Hodgkin lymphomas was terminated; res…
-
CLINICAL_TRIALS trial_result · 2017-05-11Clinical Trial Update: Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas [Phase 3]
Phase 3 trial evaluating idelalisib (GS-1101) with rituximab in previously treated indolent non-Hodgkin lymphoma was terminated with posted …
-
CLINICAL_TRIALS trial_result · 2017-05-09Clinical Trial Update: High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas [Phase 2]
Phase 2 results are reported for high-dose rituximab as initial therapy for indolent non-Hodgkin lymphoma. The trial has completed, with res…
-
CLINICAL_TRIALS trial_result · 2017-05-05Clinical Trial Update: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma [Phase 2]
A Phase II randomized trial compared GA101 (obinutuzumab) to Rituximab in untreated low tumor burden indolent non-Hodgkin lymphoma; results …
-
CLINICAL_TRIALS trial_result · 2017-03-13Clinical Trial Update: Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
Phase II study of vismodegib in refractory or relapsed B-cell lymphoma or chronic lymphocytic leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-12-21Clinical Trial Update: Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma [Phase 1, Phase 2]
Clinical trial update for idelalisib (GS-1101) in previously treated indolent non-Hodgkin's lymphoma, including follicular lymphoma, reporti…
-
CLINICAL_TRIALS trial_result · 2016-11-17Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) [Phase 3]
Phase 3 trial comparing bendamustine alone to bendamustine plus obinutuzumab in rituximab-refractory indolent non-Hodgkin's lymphoma complet…
-
CLINICAL_TRIALS trial_result · 2016-10-06Clinical Trial Update: A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma [Phase 1]
Phase 1 study evaluating TRU-016 in combination with Rituximab and Bendamustine in relapsed indolent B-cell lymphoma; results posted in 2016…
-
CLINICAL_TRIALS trial_result · 2016-06-21Clinical Trial Update: Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
A multicenter registry examining treatments and outcomes for patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2016-04-01Clinical Trial Update: Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 study evaluating SAR245409 in combination with rituximab or bendamustine plus rituximab in patients with indolent non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
A completed clinical trial update evaluating Ribomustin (bendamustine) as second-line therapy for relapsed or refractory indolent B-cell non…
-
CLINICAL_TRIALS withdrawal · 2016-02-15Clinical Trial Update: Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL [Phase 2]
A Phase 2 trial evaluating a single dose of 90Y-ibritumomab tiuxetan in patients with low tumor burden, untreated or indolent non-Hodgkin ly…